Raymond James Financial
RCUS icon

Raymond James Financial’s Arcus Biosciences RCUS Stock Holding History

Raymond James Financial’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$816K Sell
37,766
-3,058
-7% -$66K ﹤0.01% 3999
2025
Q4 		$973K Buy
40,824
+5,257
+15% +$107K ﹤0.01% 3795
2025
Q3 		$484K Buy
35,567
+181
+0.5% +$1.88K ﹤0.01% 4136
2025
Q2 		$288K Sell
35,386
-497
-1% -$4.25K ﹤0.01% 4310
2025
Q1 		$282K Buy
35,883
+221
+0.6% +$2.56K ﹤0.01% 4253
2024
Q4 		$531K Buy
+35,662
New +$582K ﹤0.01% 3868

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Raymond James Financial's RCUS Position: Q1 2026 in Review

Raymond James Financial reduced its Arcus Biosciences (RCUS) stake by 7.5% in Q1 2026, selling an estimated $66K and leaving 37,766 shares worth $816K. The position accounts for ﹤0.01% of the portfolio, ranked #3999.

Raymond James Financial first reported a position in RCUS in Q4 2024 and has held it in 6 quarters since. The position peaked at $973K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Raymond James Financial held 37,766 shares of Arcus Biosciences worth $816K as of Q1 2026.
  • Raymond James Financial sold 3,058 Arcus Biosciences shares in Q1 2026, an estimated $66K.
  • Arcus Biosciences made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3999 holding.
  • Raymond James Financial first reported a position in Arcus Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Arcus Biosciences position peaked at $973K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.